structural basis egfr ligand sequestration argos 
members epidermal growth factor receptor egfr erbb/ family activating ligands essential regulators diverse developmental processes inappropriate activation receptors key feature many human cancers reversal important clinical goal natural secreted antagonist egfr signalling called argos identified drosophila showed previously argos functions directly binding sequestering growth factor ligands activate egfr describe -angstrom resolution crystal structure argos bound egfr ligand contrary expectations argos contains egf like domain instead trio closely related domains resembling three finger toxin fold form clamp like structure around bound egf ligand although structurally unrelated receptor argos mimics egfr using bipartite binding surface entrap egf individual argos domains share unexpected structural similarities extracellular ligand binding regions transforming growth factor-beta family receptors three domain clamp argos also resembles urokinase type plasminogen activator upa receptor uses similar mechanism engulf egf like module upa results indicate undiscovered mammalian counterparts argos may exist among poorly characterized structural homologues addition structures presented define requirements design artificial egf sequestering proteins valuable anti cancer therapeutics 
